SAN CARLOS, Calif., July 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2008 on Wednesday, August 6, 2008, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
The press release and a live audio-only Webcast of the conference call
can be accessed through a link that is posted on the home page and Investor
Relations section of the Nektar website: http://www.nektar.com. The web
broadcast of the conference call will be available for replay through
Wednesday, August 20, 2008.
To access the conference call, follow these instructions:
Dial: (866) 831-5605 (U.S.); (617) 213-8851 (international)
Passcode: 33430853 (Howard Robin is the host)
An audio replay will also be available shortly following the call through Wednesday, August 20, 2008 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 67859021.
In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.
Nektar Therapeutics is a biopharmaceutical company that develops and
enables differentiated therapeutics with its industry-leading PEGylation
and pulmonary drug development platforms. Nektar's technology and drug
development expertise have enabled nine approved products for partners,
which include leading biopharmaceutical companies. Nektar is also
developing a robust pipeline of its own high-value therapeutics that
addresses unmet medical needs by leveraging and expanding its technology
platforms to improve and enable molecules.
Nektar Therapeutics 201 Industrial Road San Carlos, CA 94070
650-631-3100 Phone 650-631-3150 Fax http://www.nektar.com
|SOURCE Nektar Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved